Drug lookup | Fillwise

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Euro-Fer (02237556). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

FERROUS FUMARATE

Form:

3 of 3 products shown

2 general benefit · 1 not a benefit

Palafer · PIN 01923439 · 60mg/mL · oral liquid

General benefitOntario PIN; no Health Canada record under this code

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Palafer · DIN 01923439 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Palafer: Formulary list price $0.1092/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1092 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01923439)

Source record

DIN 01923439: Palafer Raw flags: sec3=Y Item: 200400003; group id 247; item number 0439; lccId None; manufacturer id GSK Source form: O/L; strength: 60mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1092; ministry $0.1092 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01923439 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01923439

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Fer · PIN 80024232 · 300mg · capsule

General benefitOntario PIN; no Health Canada record under this code

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Jamp-Fer · DIN 80024232 Manufacturer: Jamp Pharma Corporation; listing date 2016-01-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Jamp-Fer: Formulary list price $0.1057/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1057 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 80024232)

Source record

DIN 80024232: Jamp-Fer Raw flags: chronicUseMed=Y, sec3=Y Item: 200400013; group id 247; item number 0438; lccId None; manufacturer id JPC Source form: Cap; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1057; ministry $0.1057 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=80024232 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Palafer · DIN 01923420 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Palafer · PIN 01923420 · 300mg · capsule

Listed, not a benefitOntario PIN; no Health Canada record under this code

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Palafer · DIN 01923420 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Palafer: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 01923420)

Source record

DIN 01923420: Palafer Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 200400013; group id 247; item number 0438; lccId None; manufacturer id GSK Source form: Cap; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01923420 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Jamp-Fer · DIN 80024232 · $0.1057

Shortage record checked 2026-09-13T08:10:21.292534+00:00

FERROUS SULFATE

All products: general benefit

Fer-In-Sol · PIN 00762954 · 75mg/mL · oral liquid

General benefitOntario PIN; no Health Canada record under this code

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Fer-In-Sol · DIN 00762954 Manufacturer: Mead Johnson Canada; listing date 1997-01-03 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Fer-In-Sol: Formulary list price $0.2436/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2436 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00762954)

Source record

DIN 00762954: Fer-In-Sol Raw flags: sec3=Y Item: 200400007; group id 249; item number 0441; lccId None; manufacturer id MJS Source form: O/L; strength: 75mg/mL Recorded listing: General benefit Source prices (unrounded): $0.2436; ministry $0.2436 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00762954 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (20:04 Antianemia Drugs) and how they are covered

Matched class: 20:04 Antianemia Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): FERROUS GLUCONATE 20:04 Antianemia Drugs

FERROUS GLUCONATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 300mg · Tab

(IRON) FERRIC CARBOXYMALTOSE

· 1 products · Limited Use, codes 735, 736 · strengths: 50mg/mL · Inj Sol

FERRIC DERISOMALTOSE

· 1 products · Limited Use, codes 610 · strengths: 100mg elemental iron/mL · Inj Sol (Preservative-Free)

IRON SUCROSE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg/mL · Inj Sol-5mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:04

Full class listing Related classes: 20:12 Coagulants and Anti-Coagulants, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

Product monograph unavailable: no marketed product found

What the Health Canada label says it is for

Product monograph unavailable: no marketed product found

Other review policies

For Palafer: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026